JPS6178729A - 免疫賦活化作用成分 - Google Patents
免疫賦活化作用成分Info
- Publication number
- JPS6178729A JPS6178729A JP59199412A JP19941284A JPS6178729A JP S6178729 A JPS6178729 A JP S6178729A JP 59199412 A JP59199412 A JP 59199412A JP 19941284 A JP19941284 A JP 19941284A JP S6178729 A JPS6178729 A JP S6178729A
- Authority
- JP
- Japan
- Prior art keywords
- chlorella
- component
- immuno
- marine
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims abstract description 20
- 150000004676 glycans Chemical class 0.000 claims abstract description 7
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 7
- 239000005017 polysaccharide Substances 0.000 claims abstract description 7
- 230000003308 immunostimulating effect Effects 0.000 claims description 11
- 239000004615 ingredient Substances 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 12
- 239000013505 freshwater Substances 0.000 abstract description 5
- 230000016784 immunoglobulin production Effects 0.000 abstract description 5
- 206010028980 Neoplasm Diseases 0.000 abstract description 4
- 240000009108 Chlorella vulgaris Species 0.000 abstract description 2
- 235000007089 Chlorella vulgaris Nutrition 0.000 abstract description 2
- 241000195659 Neodesmus pupukensis Species 0.000 abstract description 2
- 230000035755 proliferation Effects 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 208000006268 Sarcoma 180 Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000009240 nasopharyngitis Diseases 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000000843 powder Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 241001494479 Pecora Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241000133289 Progoniada regularis Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002747 voluntary effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/946—Microorganisms using algae
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59199412A JPS6178729A (ja) | 1984-09-26 | 1984-09-26 | 免疫賦活化作用成分 |
| US06/777,169 US4831020A (en) | 1984-09-26 | 1985-09-18 | Ingredient effective for activating immunity obtained from Chlorella minutissima |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59199412A JPS6178729A (ja) | 1984-09-26 | 1984-09-26 | 免疫賦活化作用成分 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6178729A true JPS6178729A (ja) | 1986-04-22 |
| JPH0517888B2 JPH0517888B2 (enExample) | 1993-03-10 |
Family
ID=16407371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59199412A Granted JPS6178729A (ja) | 1984-09-26 | 1984-09-26 | 免疫賦活化作用成分 |
Country Status (2)
| Country | Link |
|---|---|
| US (1) | US4831020A (enExample) |
| JP (1) | JPS6178729A (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63316733A (ja) * | 1987-06-18 | 1988-12-26 | Kureha Chem Ind Co Ltd | 抗ウイルス剤 |
| US6551596B2 (en) | 2000-08-10 | 2003-04-22 | Ocean Nutrition Canada Limited | Fractions of Chlorella extract containing polysaccharide having immunomodulating properties |
| JP2008184120A (ja) * | 2007-01-31 | 2008-08-14 | Iseki & Co Ltd | トラクタ |
| JP2011522911A (ja) * | 2008-05-06 | 2011-08-04 | オーシャン ニュートリッション カナダ リミテッド | 免疫調節特性を有するクロレラ抽出物から得られる組成物 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1332650C (en) * | 1987-06-18 | 1994-10-18 | Kunitaka Hirose | Polysaccharides and antiviral drugs containing the same as active ingredient |
| US7205284B2 (en) * | 2000-07-10 | 2007-04-17 | University Of Mississippi | Potent immunostimulants from microalgae |
| CN116655817B (zh) * | 2023-04-25 | 2024-06-25 | 河南澳爱丝生物科技有限公司 | 一种酶解耦合深共熔溶剂提取极微小球藻多糖的方法及应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5815920A (ja) * | 1981-07-23 | 1983-01-29 | Kurorera Kogyo Kk | リンパ球増加剤 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3939279A (en) * | 1969-08-22 | 1976-02-17 | Asahi Kasei Kogyo Kabushiki Kaisha | Feed and method of aquianimals cultivation |
| US4254257A (en) * | 1979-02-21 | 1981-03-03 | The Lubrizol Corporation | Amine salts of acidic microbial polysaccharides and their use in recovery of such polysaccharides |
| JPS5896025A (ja) * | 1981-12-02 | 1983-06-07 | Kitasato Inst:The | 新規生理活性物質ｃｈ−１およびその製造法 |
| JP3104277B2 (ja) * | 1991-04-16 | 2000-10-30 | ブラザー工業株式会社 | 画像記録方法 |
-
1984
- 1984-09-26 JP JP59199412A patent/JPS6178729A/ja active Granted
-
1985
- 1985-09-18 US US06/777,169 patent/US4831020A/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5815920A (ja) * | 1981-07-23 | 1983-01-29 | Kurorera Kogyo Kk | リンパ球増加剤 |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63316733A (ja) * | 1987-06-18 | 1988-12-26 | Kureha Chem Ind Co Ltd | 抗ウイルス剤 |
| US6551596B2 (en) | 2000-08-10 | 2003-04-22 | Ocean Nutrition Canada Limited | Fractions of Chlorella extract containing polysaccharide having immunomodulating properties |
| US6974576B2 (en) | 2000-08-10 | 2005-12-13 | Ocean Nutrition Canada Limited | Chlorella composition having high molecular weight polysaccharides and polysaccharide complexes |
| US6977076B2 (en) | 2000-08-10 | 2005-12-20 | Ocean Nutrition Canada Limited | Methods for obtaining from Chlorella extract polysaccharides having immunomodulating properties |
| JP2008184120A (ja) * | 2007-01-31 | 2008-08-14 | Iseki & Co Ltd | トラクタ |
| JP2011522911A (ja) * | 2008-05-06 | 2011-08-04 | オーシャン ニュートリッション カナダ リミテッド | 免疫調節特性を有するクロレラ抽出物から得られる組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0517888B2 (enExample) | 1993-03-10 |
| US4831020A (en) | 1989-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Landy et al. | Humoral and cellular aspects of the immune response to the somatic antigen of Salmonella enteritidis | |
| US6379714B1 (en) | Pharmaceutical grade botanical drugs | |
| Dutton | Inhibitory and stimulatory effects of concanavalin A on the response of mouse spleen cell suspensions to antigen: I. Characterization of the inhibitory cell activity | |
| LEVINE et al. | Suramin antiviral therapy in the acquired immunodeficiency syndrome: Clinical, immunologic, and virologic results | |
| Lamon et al. | The lymphocyte response to a primary viral neoplasm (MSV) through its entire course in BALB/c mice | |
| Goulmy et al. | Cell-mediated lympholysis studies in renal allograft recipients | |
| Yamamoto | Lytic Activity of C5̄‑9̄ Complexes for Erythrocytes from the Species Other Than Sheep: C9 Rather Than C8-Dependent Variation in Lytic Activity | |
| US5780037A (en) | Mistletoe extract and method | |
| Burger et al. | Human transfer factor: fractionation and biologic activity | |
| JPS6178729A (ja) | 免疫賦活化作用成分 | |
| WO1996032122A9 (en) | Mistletoe extract and method | |
| Herberman et al. | Cellular Immune Reactions to Human Leu-kemia¹, 2 | |
| Ebert et al. | Selective immunosuppressive action of a factor produced by colon cancer cells | |
| Hršak et al. | Mode of immunosuppressive action of Ehrlich ascitic fluid | |
| Cormane et al. | Immunologic implications of PUVA therapy in psoriasis vulgaris | |
| Eidinger et al. | Studies of Antibody Formation in Vitro and in Lethally Irradiated Reconstituted Mice: Evidence for an Inhibitory Function of Thymus‐Derived Cells | |
| Kucich et al. | The Protein Nature of the Thy-1.2 Alloantigen as Expressed by the Murine Lymphoblastoid Line S-49.1 TB· 2· 3 | |
| MacSween et al. | Phytohaemagglutinin (PHA) induced lymphocyte transformation and Toxoplasma gondii antibody studies in primary biliary cirrhosis. Evidence of impaired cell-mediated immunity | |
| Petrini et al. | T helper/suppressor ratios in chemotherapy and radiotherapy | |
| De Vecchis et al. | Decline of natural cytotoxicity of human lymphocytes following infection with human T-cell leukemia/lymphoma virus (HTLV) | |
| Merwin | Repopulation of hematopoietic tissues of X-irradiated mice by cells from leukemoid blood | |
| Sasaki et al. | Antitumor Activity of a Boiled Scallop Extract: Brief Communication | |
| Keyser | Effect of nitrogen mustard or X-or radium-irradiation treatment on the level of blood serum protein-bound carbohydrate (polysaccharide) in patients with neoplastic diseases | |
| Jacobsson et al. | Evidence for a loss of recirculation capacity of T-cells after antigenic stimulation | |
| DeLarco et al. | The synthesis of RNA which binds to oligo (dT)-cellulose by brain in, vivo and in, vitro |